Lolu luhlu lwemibono ka-Alexandria, isakhamuzi saseZimbabwe futhi obenza unyaka wesibili wezokuphatha ibhizinisi e-Liaoning Shuhua University eChina.

SINGAPORE, Feb 23, 2022 - (ACN Newswire) - I-Catalist efakwe ohlwini i-Aoxin Q&M Dental Limited ("Aoxin" noma "iQembu"), namuhla imemezele ukwenyuka kwenzuzo ngo-20.8% kuya ku-RMB160.2 wezigidi ngonyaka ophelele ophele zingama-31 kuZibandlela wezi-2021 ( "FY2021"). IQembu libike ukulahlekelwa okuphelele ngemva kwentela ka-RMB7.3 wezigidi ze-FY2021, ukuthuthuka kusukela ekulahlekeni kwensalela kwezigidi ezingu-RMB12.1 kusukela onyakeni odlule. Ngo-2020, ngenxa yesimo se-COVID-19, uhulumeni waseChina unikeze usizo lwesikhashana emabhizinisini ngokuhoxisa iminikelo yomshwalense wezokuphepha komphakathi. I-Aoxin izoba nezindleko ezengeziwe ezingu-RMB6.3 wezigidi zezindleko zomshwalense wokuvikela umphakathi ezirekhodwe ngo-FY2020 okuholela Ekulahlekeni Kwesamba sezigidi ezingu-RMB18.4, esikhundleni sezigidi ezingu-RMB12.1.
UDkt. Shao Yongxin, oyi-Group Chief Executive Officer ye-Aoxin Q&M uthe, "Amathemba ezomnotho emhlabeni wonke ka-2022 azoqhubeka nokungaqiniseki, njengoba amazwe amaningi asazabalaza ukuqukatha ukusabalala okusheshayo kwe-Omicron variant. Amathuba ezinhlobo ezintsha ze-COVID-19 ngeke Kodwa-ke, izinsizakalo zamazinyo ze-Aoxin Q&M ziyenza iqine futhi ibekwe kahle ikhiphe ukwehla okukhona manje ukuze isebenzise amathuba abalulekile emkhakheni wezempilo we-post-COVID".

UMnu Ryan San, iPhini leSikhulu Esiphezulu se-Aoxin Q&M uthe, "Iqembu belisebenza endaweni enenselelo, elithinteke kakhulu ukuvalwa okuphindelelayo kwamadolobha e-People's Republic of China ("PRC"). buka isimo se-COVID-19 esiguqukayo ku-PRC, kuyilapho siphatha izindleko zethu ngokuziphatha okuqinile."

Imali engenayo

Imali engenayo yeQembu inyuke ngezigidi ezingu-RMB27.6 noma u-20.8%, isuka ezigidini ezingu-RMB132.6 ngo-FY2020 yaya ku-RMB160.2 wezigidi ngo-FY2021, ikakhulukazi ngenxa yokululama kuzo zonke izingxenye zebhizinisi.

Imali engenayo evela engxenyeni yokunakekelwa kwezempilo okuyisisekelo inyuke ngo-19.7% isuka ezigidini ezingama-RMB78.5 ngo-FY2020 yaya ku-RMB93.9 million ngo-FY2021. Ukwanda kwemali engenayo kwakuvela ezibhedlela zethu ezibalulekile emadolobheni aseShenyang naseDalian, kanye ne-polyclinic edolobheni lasePanjin ikakhulukazi ngenxa yokwanda kweziguli.

Imali engenayo ngokusatshalaliswa kwezinto zokusebenza zamazinyo nengxenye yezimpahla izuze ukukhula okuphawulekayo kwama-24.8%. Imali engenayo ibingu-RMB50.4 wezigidi ngo-FY2021 uma iqhathaniswa nezigidi ezingama-RMB40.4 ngo-FY2020. Kube nesidingo esikhulu sezinsizakusebenza zamazinyo ezivela ezibhedlela zikahulumeni phakathi nokusimama komnotho kancane kancane eChina okusekelwa ukukhishwa kokugomela i-COVID-19 ezweni.

Imali engenayo evela engxenyeni yezinsizakalo zaselabhorethri ikhuphuke ngo-15.9% yafinyelela ku-RMB15.9 million ngo-FY2021 uma kuqhathaniswa nezigidi ezingu-RMB13.7 ngo-FY2020 ngenxa yokwanda kwesidingo salezo zinsizakalo ezibhedlela zikahulumeni zamazinyo eDolobheni laseShenyang.

I-EBITDA

I-EBITDA yeQembu nayo inyuke isuka ezigidini ezingu-RM9.5 ngo-FY2020 yaya ku-RMB13.9 wezigidi ngo-FY2021. Ukwenyuka kwe-EBITDA kudalwe ikakhulukazi imali engenayo ephezulu nokusebenza okungcono okuvela ezibhedlela zamazinyo ezibalulekile kanye nama-polyclinics kanye nokuthengiswa okuphezulu kwemishini yamazinyo nempahla. Naphezu kwe-EBITDA enhle yezigidi ezingu-RMB13.9, Iqembu liqophe ukulahlekelwa kwezigidi ezingu-RMB7.3 ngenxa yokukhushulwa kweholo kanye nezindleko zokuqasha, kanye nezinye izindleko eziphakeme, ezifana nezinkokhelo ezihlobene nokutholakala kwe-Acumen Diagnostics Pte. Ltd. ("I-Acumen Diagnostics") nezinye izindleko zentela.

UMnu Ryan San, iPhini Lesikhulu Esiphezulu se-Aoxin Q&M kwengezwe. "Sithemba futhi ukuthi ukuya phambili, ukuzuza kwethu kwakamuva ingxenye engu-49% ku-Acumen Diagnostics kuzothuthukisa inzuzo nokugeleza kwemali kweQembu. Ngobuchwepheshe be-Acumen Diagnostics ku-R&D kanye nokuxilongwa kwezokwelapha sizokwazi ukudlala indima ebalulekile ekusekeleni. wesu likahulumeni wase-Singapore lokuphila ne-COVID-19 Ngokuhambisanayo, lokhu kuzoba nomthelela ekukhuleni kweQembu.

Izibuyekezo ku-associate - I-Acumen Diagnostics

- Amandla Okubhekana ne-Omicron COVID-19 Variant

I-Acumen Diagnostics izoqhubeka nokuhlinzeka ngokuhlolwa kwe-COVID-19 nge-polymerase chain reaction ("PCR") ezigulini ezidinga imiphumela yokuhlolwa kwe-PCR kanye nakubahambi njengoba iSingapore ivula imingcele yayo, kanye nokusabalalisa izivivinyo ezisheshayo ze-COVID-19 antigen ("ART"). . Izophinde yethule iphaneli yokuhlola okusha kwe-PCR kwezifo ezithathelwanayo, i-sepsis nomdlavuza.

Ngomhla zi-3 kuZibandlela wezi-2021, i-Acumen Diagnostics yamemezela ukuthi izinsiza zayo zokuhlola ze-PCR eziphathelene, ezikhiqizwe endaweni i-Acu-Corona 2.0 kanye ne-Acu-Corona Duplex ziyakwazi ukuthola amacala ane-COVID-19 angenwe okuhlukile kwe-Omicron. Mhla ziyi-16 kuZibandlela wezi-2021, i-Acumen Diagnostics yamemezela ukuthi inikezwe ilayisense nguMnyango Wezempilo, eSingapore ukuhlinzeka ngezinsizakalo ze-COVID-19 PCR swab kanye nokuqoqwa kwesampula ye-serology emitholampilo eyi-100.

I-Acumen Diagnostics izoqhubeka nokukhipha izinsiza zayo zokuhlola ngenethiwekhi yemitholampilo ye-Q&M Dental Group Limited, kanye nasendlunkulu yayo ese-The Gemini, 41 Science Park Road, Singapore. Njengamanje, i-Acumen Diagnostics inemitholampilo engaba ngu-61 ehlinzeka ngezinsizakalo zokuhlola esiqhingini sonke.

- Ukufakwa kuhlu okuhlongozwayo ku-NASDAQ stock exchange maqondana ne-Acumen Diagnostics Pte. Ltd.

Ngomhla ziyi-17 kuMasingana 2022, i-Aoxin yamemezela ukuthi inkampani ehlobene yeQembu, i-Acumen Diagnostics ihlola uhlu oluhlongozwayo lwezibambiso zayo ku-NASDAQ stock exchange eNew York, e-USA. Mayelana nalokhu, i-Acumen Diagnostics iqoke i-UOB Kay Hian Private Limited ukuthi isize i-Acumen Diagnostics ngokuhlolwa kohlu kanye nawo wonke umsebenzi wokulungiselela ofanelekile ohlanganisa ukukhethwa kwabeluleki abangochwepheshe kanye namabhange abhala ngaphansi maqondana nomsebenzi wokufakwa kuhlu ohlongozwayo kanye nokuqoqwa kwezimali.

Ngibheke phambili

Imiphumela ye-Aoxin's FY2021 ibonisa ukukhuphuka okukhulu kwemali engenayo uma kuqhathaniswa nemali engenayo ye-FY2020 okwakuyinkathi lapho ubhubhane lwe-COVID-19 ku-PRC lwalusesigabeni esibucayi kakhulu. Njengoba isimo se-COVID-19 ku-PRC siqhubeka nokuba ngcono, silindele ukuthi imali engenayo yeQembu ithuthuke ngokufanayo.

Ngaphezu kwalokho, ukutholwa kwakamuva okungama-49% kwenkampani yobuchwepheshe bezokwelapha, i-Acumen Diagnostics kwezigidi ezingu-S$29.4 ngomhla ka-1 Novemba 2021, kuzothuthukisa inzuzo yeQembu ukuya phambili.

Indawo yebhizinisi kulindeleke ukuthi ihlale iyinselelo ngonyaka ozayo, njengoba amazwe amaningi okuhlanganisa ne-PRC elwela ukuqukatha ukusabalala kwegciwane le-COVID-19 okukhonjiswa amagagasi amasha okutheleleka.

IQembu lizoqhubeka nokugxila ekuphathweni ngendlela efanele kwezindleko zokusebenza, izindleko kanye nezindleko ezinkulu. IQembu lizoqhubeka nokuqapha izindleko zalo futhi likhulise ukusebenza kahle kwezindleko zokusebenza.

Ngaphandle kwanoma yiziphi izimo ezingalindelekile kanye nokubhebhetheka okuqhubekayo kwesimo se-COVID-19 njengokuvalelwa kwesikhashana noma ukuvalwa kwesikhashana emadolobheni esisebenzela kuwo, azikho izinguquko ezibalulekile ezaziwayo ezinkambisweni nasezimeni zokuncintisana zemboni lapho iQembu lisebenza khona futhi azikho ezinye izici ezinkulu ezaziwayo noma izehlakalo ezingase zibe nomthelela omubi IQembu esikhathini sokubika esilandelayo nasezinyangeni eziyi-12 ezizayo. IQembu lizoqhubeka nokuqapha izindleko zalo zokusebenza futhi likhulise ukusebenza kahle kwezindleko zokusebenza.

Ukuze uthole ulwazi olwengeziwe, sicela ubheke amafayela anamathiselwe noma izixhumanisi ezingezansi:
https://links.sgx.com/FileOpen/AoxinPressRelease-FY2021_okokugcina_23.2.22.ashx?App=Isimemezelo&FileID=703172
https://links.sgx.com/FileOpen/AXQM%20Announcement%20FY2021.ashx?App=Announcement&FileID=703171

Lesi simemezelo sibuyekezwe umxhasi weNkampani, i-PrimePartners Corporate Finance Pte. Ltd. ("Umxhasi"). Ayihloliwe noma yagunyazwa yi-Singapore Exchange Securities Trading Limited ("I-Exchange") futhi i-Exchange ayithwesi umthwalo wemfanelo ngokuqukethwe kwalo mbhalo, okuhlanganisa nokunemba kwanoma yiziphi izitatimende noma imibono eyenziwe noma imibiko equkethwe kulo mbhalo. .

Umuntu ongathintwa Umxhasi nguNkz. Lim Hui Ling, 16 Collyer Quay, #10-00 Income e-Raffles, Singapore 049318, [i-imeyili ivikelwe]

Mayelana ne-Aoxin Q&M Dental Group Limited (Ikhodi yesitoko: 1D4.SI) www.aoxinqm.com.sg

I-Aoxin Q&M Dental Group Limited ("i-Aoxin Q&M" noma kanye nezinkampani ezingaphansi kwayo, "Iqembu") ingumhlinzeki oholayo wezinkonzo zamazinyo ezizimele eSifundazweni sase-Liaoning, eNyakatho Yabantu baseRiphabhulikhi yaseChina ("PRC"). IQembu lisebenza ngezikhungo zamazinyo eziyi-16, ezihlanganisa izikhungo zamazinyo eziyi-10 kanye nezibhedlela zamazinyo eziyisi-6, ezitholakala kuwo wonke amadolobha angu-8 esiFundazweni saseLiaoning, okuyiShenyang, iHuludao, iPanjin, iGaizhou, iZhuanghe, iJinzhou, iDalian ne-Anshan.

Njengamanje sinochwepheshe bamazinyo abangu-400, okuhlanganisa odokotela bamazinyo abangu-170, abasizi bamazinyo abangu-180 kanye nochwepheshe baselabhorethri abangu-50.

Iningi lezikhungo zamazinyo zigunyazwe njengeZikhungo Eziqokiwe Zezokwelapha Zomshuwalense Wezempilo. Ukwengeza, iQembu lizibophezele ekuhlinzekweni kwezinsiza zaselabhorethri yamazinyo, kanye nokusatshalaliswa nokudayiswa kwemishini yamazinyo kanye nempahla esiFundazweni sase-Liaoning, i-Heilongjiang kanye ne-Jilin eNyakatho ye-PRC.

I-Aoxin Q&M isohlwini lwebhodi ye-Catalist ye-Singapore Exchange Securities Trading Limited ngomhla zingama-26 kuMbasa wezi-2017.

Mayelana ne-Acumen Diagnostics Pte. Ltd. (www.acumen-research.com)

I-Acumen Diagnostics Pte. I-Ltd. ("I-Acumen Diagnostics") iyinkampani yobuchwepheshe bezokwelapha ezuza umklomelo eSingapore. Ihlanganiswe ngokugcwele nemisebenzi ocwaningweni nasekuthuthukisweni, ekukhiqizeni, kanye nasekuhwebeni kokuxilongwa kwamangqamuzana ngokusatshalaliswa kanye nokwenza izinsizakalo zokuhlola ilabhorethri yomtholampilo (kuhlanganise kodwa kungagcini nje) kwezifo ezithathelwanayo, umdlavuza, kanye ne-COVID-19. Iphinde yasungula izinsiza ezihamba phambili ezifana nokusebenza kwe-COVID-19 kusayithi.

I-Acumen Diagnostics iyingxenye engu-51% ye-SGX esohlwini lwe-Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) kanye no-49% ephethwe yi-SGX esohlwini lwe-Aoxin Q&M Dental Group Limited (SGX: QC7.SI).

Abezindaba nabahlaziyi: sicela uthinte ngezansi ukuze uthole ulwazi olwengeziwe: I-Waterbrooks Consultants Pte. Ltd.
+65 6958 8008, [i-imeyili ivikelwe]
Wayne Koo (M): +65 9338 8166, [i-imeyili ivikelwe]
U-Derek Yeo (M): +65 9791 4707, [i-imeyili ivikelwe]

Copyright 2022 ACN Newswire. Wonke Amalungelo Agodliwe. www.acnnewswire.comCatalist esohlwini lwe-Aoxin Q&M Dental Limited ("Aoxin" noma "iQembu"), namuhla imemezele ukwenyuka kwenzuzo ngo-20.8% kuya ku-RMB160.2 wezigidi ngonyaka ophelele ophele zingama-31 kuZibandlela wezi-2021 ("FY2021").